Barclays raised the firm’s price target on Anteris Technologies (AVR) to $18 from $17 and keeps an Overweight rating on the shares. The company’s Q1 results included an update on the PARADIGM pivotal trial and efforts to activate additional centers and enroll new patients in the trial, the analyst tells investors in a research note. The firm says enrollment is on track to complete by Q1 of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
- Anteris Technologies Adds Experienced Financial Leaders to Board
- Anteris Technologies: First U.S. patients treated in global PARADIGM trial
- Anteris Ends v2vmedtech Development Agreement, Limits Exposure
- Anteris Technologies secures CMS reimbursement for trial site activation
- Anteris Technologies Signs Major Brooklyn Park Facility Lease